Skip to Main Content

Intracellular Therapeutics Pipeline

Diverse and Expanding Pipeline of RNA-, Antibody- and Enzyme-Based Programs Spanning Discovery and Clinical Development

At Entrada Therapeutics, we are driven to transform the lives of patients by establishing a new class of intracellular therapeutics. We are already developing potential treatments across multiple devastating diseases with a simple and scalable EEV platform designed to translate from preclinical to clinical development.

Learn more about our proprietary EEV™ Platform.

Duchenne Muscular Dystrophy (DMD)

ENTR-601-44 (Exon 44 Skipping Oligonucleotide)

Duchenne Muscular Dystrophy
Discovery 100% complete
Lead Optimization 100% complete
IND Enabling 100% complete
Clinical 22% complete

ENTR-601-45 (Exon 45 Skipping Oligonucleotide)

Duchenne Muscular Dystrophy
Discovery 100% complete
Lead Optimization 100% complete
IND Enabling 100% complete
Clinical 5% complete

ENTR-601-50 (Exon 50 Skipping Oligonucleotide)

Duchenne Muscular Dystrophy
Discovery 100% complete
Lead Optimization 100% complete
IND Enabling 75% complete
Clinical 0% complete

Exon 51 (Exon 51 Skipping Oligonucleotide)

Duchenne Muscular Dystrophy
Discovery 100% complete
Lead Optimization 100% complete
IND Enabling 30% complete
Clinical 0% complete

Myotonic Dystrophy Type 1 (DM1)

VX-670 (Oligonucleotide) 1

Myotonic Dystrophy Type 1
Discovery 100% complete
Lead Optimization 100% complete
IND Enabling 100% complete
Clinical 40% complete

Pipeline Expansion

Undisclosed Ocular

Discovery 100% complete
Lead Optimization 90% complete
IND Enabling 0% complete
Clinical 0% complete

Undisclosed Programs

Discovery 100% complete
Lead Optimization 55% complete
IND Enabling 0% complete
Clinical 0% complete

Platform Expansion

Discovery 100% complete
Lead Optimization 0% complete
IND Enabling 0% complete
Clinical 0% complete
References
  1. 1.

    In collaboration with

    Vertex Pharmaceuticals